Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Andrew M. Waters

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6058-5878; OpenAlex author ID A5031911025; NIH RePORTER profile ID 14892518. Sources: funder_awards.

Their work

Papers
12 (first author 1, last author 2)
Trials
0
Grants
2
Labs led
1
Collaborators
61
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers, 1 grant · 2026: 2 papers, 1 grant

Papers 12

  1. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Co-author DOI 10.1016/j.celrep.2026.117627↗
  2. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-25-1835↗
  3. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. Co-author DOI 10.1126/scisignal.adu7145↗
  4. Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells. Co-author DOI 10.1158/1078-0432.ccr-24-2183↗
  5. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment. Last author DOI 10.3389/fonc.2024.1402128↗
  6. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-22-0391↗
  7. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Co-author DOI 10.1016/j.celrep.2021.109291↗
  8. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Co-author DOI 10.1016/j.celrep.2021.110060↗
  9. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  10. Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-1006↗
  11. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗
  12. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Co-author DOI 10.1101/cshperspect.a031435↗

Grants 2

  1. Determining the role of KSR in mediating resistance to KRAS inhibition in PDAC AWARD pancan:2026-andrew-m-waters-phd-determining-the-role-of-ksr-in-mediating
  2. Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancer K22CA276632↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Channing J. Der · 10 shared papers, 2018–2026 · strength 1.29
  2. Adrienne D. Cox · 9 shared papers, 2019–2026 · strength 1.11
  3. Clint A. Stalnecker · 8 shared papers, 2019–2026 · strength 1.04
  4. Jennifer E. Klomp · 8 shared papers, 2019–2026 · strength 0.90
  5. Kirsten L. Bryant · 7 shared papers, 2019–2026 · strength 0.84
  6. Craig M. Goodwin · 6 shared papers, 2020–2026 · strength 0.79
  7. J. Nathaniel Diehl · 7 shared papers, 2019–2026 · strength 0.77
  8. Bjoern Papke · 7 shared papers, 2019–2026 · strength 0.72
  9. G. Aaron Hobbs · 6 shared papers, 2019–2026 · strength 0.70
  10. A. Cole Edwards · 4 shared papers, 2021–2026 · strength 0.67
  11. Mariaelena Pierobon · 6 shared papers, 2019–2025 · strength 0.63
  12. Andrew J. Aguirre · 4 shared papers, 2020–2026 · strength 0.57
  13. Szu-Aun Lim · 2 shared papers, 2024–2026 · strength 0.49
  14. Priya S. Hibshman · 3 shared papers, 2021–2026 · strength 0.46
  15. Lee M. Graves · 3 shared papers, 2021–2026 · strength 0.46
  16. Tikvah K. Hayes · 4 shared papers, 2019–2026 · strength 0.41
  17. Kristina Drizyte‐Miller · 3 shared papers, 2021–2025 · strength 0.41
  18. Emanuel F. Petricoin · 2 shared papers, 2023–2025 · strength 0.32
  19. Emanuel F. Petricoin · 4 shared papers, 2019–2021 · strength 0.31
  20. Syed Ameen Ahmad · 1 shared paper, 2024 · strength 0.28
  21. Devon R. Blake · 2 shared papers, 2021–2026 · strength 0.28
  22. William C. Hahn · 2 shared papers, 2021–2026 · strength 0.28
  23. Julien Dilly · 1 shared paper, 2026 · strength 0.21
  24. Syed Arif Ahmad · 1 shared paper, 2026 · strength 0.21
  25. Sarah E. Ackermann · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.